Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 36, No. 6, 2004
Issue release date: November – December
Section title: Original Paper
Eur Surg Res 2004;36:331–337

Attenuation of Leukocyte Sequestration by Selective Blockade of PECAM-1 or VCAM-1 in Murine Endotoxemia

Nolte D.a,b · Kuebler W.b,c · Muller W.d · Wolff K.a · Messmer K.b
aDepartment of Oral and Maxillofacial Surgery – Regional Plastic Surgery, Knappschaftskrankenhaus Bochum-Langendreer, University of Bochum, Bochum, bInstitute for Surgical Research, Ludwig Maximilian University of Munich, Munich, and cInstitute of Physiology, Charité – Universitätsmedizin Berlin, Berlin, Germany; dDepartment of Pathology and Laboratory Medicine, Weill Medical College, New York, N.Y., USA
email Corresponding Author

Dirk Nolte, MD, DDS, PhD

Department of Oral and Maxillofacial Surgery – Regional Plastic Surgery

University Clinic at the Ruhr University of Bochum, In der Schornau 23–25

DE–44892 Bochum (Germany)

Tel. +49 234 299 3502/12, Fax +49 234 299 3509, E-Mail dirk.nolte@ruhr-uni-bochum.de

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Background: Molecular mechanisms regulating leukocyte sequestration into the tissue during endotoxemia and/or sepsis are still poorly understood. This in vivo study investigates the biological role of murine PECAM-1 and VCAM-1 for leukocyte sequestration into the lung, liver and striated skin muscle. Methods: Male BALB/c mice were injected intravenously with murine PECAM-1 IgG chimera or monoclonal antibody (mAb) to VCAM-1 (3 mg/kg body weight); controls received equivalent doses of IgG2a (n = 6 per group). Fifteen minutes thereafter, 2 mg/kg body weight of Salmonella abortus equi endotoxin was injected intravenously. At 24 h after the endotoxin challenge, lungs, livers and striated muscle of skin were analyzed for their myeloperoxidase activity. To monitor intravital leukocyte-endothelial cell interactions, fluorescence videomicroscopy was performed in the skin fold chamber model of the BALB/c mouse at 3, 8 and 24 h after injection of endotoxin. Results: Myeloperoxidase activity at 24 h after the endotoxin challenge in lungs (12,171 ± 2,357 mU/g tissue), livers (2,204 ± 238 mU/g) and striated muscle of the skin (1,161 ± 110 mU/g) was significantly reduced in both treatment groups as compared to controls, with strongest attenuation in the PECAM-1 IgG treatment group. Arteriolar leukocyte sticking at 3 h after endotoxin (230 ± 46 cells × mm–2) was significantly reduced in both treatment groups. Leukocyte sticking in postcapillary venules at 8 h after endotoxin (343 ± 69 cells/mm2) was found reduced only in the VCAM-1-mAb-treated animals (215 ± 53 cells/mm2), while it was enhanced in animals treated with PECAM-1 IgG (572 ± 126 cells/mm2). Conclusion: These data show that both PECAM-1 and VCAM-1 are involved in endotoxin-induced leukocyte sequestration in the lung, liver and muscle, presumably through interference with arteriolar and/or venular leukocyte sticking.

© 2004 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: May 26, 2004
Accepted: June 25, 2004
Published online: December 03, 2004
Issue release date: November – December

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 0

ISSN: 0014-312X (Print)
eISSN: 1421-9921 (Online)

For additional information: http://www.karger.com/ESR

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.